Zoetis Inc (ZTS)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 3,123,000 | 2,940,000 | 2,659,000 | 2,491,000 | 1,998,000 |
| Revenue | US$ in thousands | 9,256,000 | 8,544,000 | 8,080,000 | 7,776,000 | 6,675,000 |
| Pretax margin | 33.74% | 34.41% | 32.91% | 32.03% | 29.93% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $3,123,000K ÷ $9,256,000K
= 33.74%
Zoetis Inc's pretax margin has shown a positive trend over the past five years, increasing from 29.93% in December 2020 to 33.74% in December 2024. This indicates that the company's ability to generate profits before taxes has improved steadily over the period. The highest pretax margin was recorded in December 2023 at 34.41%, reflecting strong operational efficiency and cost management. Overall, Zoetis Inc's pretax margin performance demonstrates consistent profitability and effective financial management strategies during the analyzed period.
Peer comparison
Dec 31, 2024
Company name
Symbol
Pretax margin
Zoetis Inc
ZTS
33.74%
Abbott Laboratories
ABT
16.90%
AbbVie Inc
ABBV
11.49%
Alkermes Plc
ALKS
28.18%
Amphastar P
AMPH
25.85%
ANI Pharmaceuticals Inc
ANIP
4.37%
Arcus Biosciences Inc
RCUS
-109.30%
Biomarin Pharmaceutical Inc
BMRN
19.04%
Bristol-Myers Squibb Company
BMY
-17.38%
Catalent Inc
CTLT
-23.44%
Catalyst Pharmaceuticals Inc
CPRX
23.73%